phenethylamine has been researched along with Parkinson Disease in 11 studies
phenethylamine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7016
2-phenylethylamine : A phenylethylamine having the phenyl substituent at the 2-position.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deprenyl/Selegiline (DEP), created by Joseph Knoll in the 1960s, registered in more than 60 countries to treat Parkinson's disease, Alzheimer's disease, major depressive disorder; and used as an anti-aging drug, achieved its place in research and therapy as the first selective inhibitor of B-type monoamine oxidase (MAO-B)." | 4.93 | The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015). ( Miklya, I, 2016) |
| " It has been reported recently that long-term administration of β-PEA in rodents causes neurochemical and behavioral alterations similar to that produced by parkinsonian neurotoxins." | 2.49 | Contribution of β-phenethylamine, a component of chocolate and wine, to dopaminergic neurodegeneration: implications for the pathogenesis of Parkinson's disease. ( Bhattacharjee, N; Borah, A; Mazumder, MK; Paul, R, 2013) |
| "Concentrations of PEA in CSF in Parkinson's disease were significantly lower (mean 205 (SD 131) pg/ml) than in patients with peripheral neuropathy (433 (SD 254) pg/ml) and controls (387 (SD 194) pg/ml)." | 1.30 | Decreased beta-phenylethylamine in CSF in Parkinson's disease. ( Matsuishi, T; Shoji, H; Yamada, S; Zhou, G, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borah, A | 1 |
| Paul, R | 1 |
| Mazumder, MK | 1 |
| Bhattacharjee, N | 1 |
| Miklya, I | 1 |
| Gluck, MR | 1 |
| Zeevalk, GD | 1 |
| Yu, PH | 1 |
| Jarman, J | 1 |
| Glover, V | 1 |
| Sandler, M | 1 |
| Turjanski, N | 1 |
| Stern, G | 1 |
| La Croix, R | 1 |
| Dostert, P | 1 |
| Strolin Benedetti, M | 1 |
| Gargalidis-Moudanos, C | 1 |
| Pizzinat, N | 1 |
| Javoy-Agid, F | 1 |
| Remaury, A | 1 |
| Parini, A | 1 |
| Yamakawa, T | 1 |
| Ohta, S | 1 |
| Zhou, G | 2 |
| Shoji, H | 2 |
| Yamada, S | 2 |
| Matsuishi, T | 2 |
| Miura, Y | 2 |
3 reviews available for phenethylamine and Parkinson Disease
| Article | Year |
|---|---|
Contribution of β-phenethylamine, a component of chocolate and wine, to dopaminergic neurodegeneration: implications for the pathogenesis of Parkinson's disease.
Topics: Animals; Cacao; Dopaminergic Neurons; Humans; Nerve Degeneration; Oxidative Stress; Parkinson Diseas | 2013 |
The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
Topics: Aging; Alzheimer Disease; Animals; Brain; Catecholamines; Depressive Disorder, Major; Dopamine; Hist | 2016 |
Pharmacological and clinical implications of MAO-B inhibitors.
Topics: Aging; Alzheimer Disease; Animals; Depressive Disorder; Humans; Mental Disorders; Monoamine Oxidase | 1994 |
8 other studies available for phenethylamine and Parkinson Disease
| Article | Year |
|---|---|
Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Catecholamines; Cell Respiration; Dopamine | 2004 |
Platelet monoamine oxidase B activity in Parkinson's disease: a re-evaluation.
Topics: Aged; Blood Platelets; Dopamine; Female; Humans; Male; Middle Aged; Monoamine Oxidase; Parkinson Dis | 1993 |
Sensitive high-performance liquid chromatographic method for the determination of 2-phenylethylamine in human urine.
Topics: Aged; Antiparkinson Agents; Chromatography, High Pressure Liquid; Circadian Rhythm; Female; Humans; | 1996 |
I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Brain; Cerebral Cortex; Female; Humans; Idazoxan; Imidazoline Receptors; Ma | 1997 |
Isolation of 1-methyl-1,2,3,4-tetrahydroisoquinoline-synthesizing enzyme from rat brain: a possible Parkinson's disease-preventing enzyme.
Topics: Animals; Brain; Chromatography, Gel; Deoxycholic Acid; Hydrogen-Ion Concentration; Isoquinolines; Ma | 1997 |
Decreased beta-phenylethylamine in CSF in Parkinson's disease.
Topics: Aged; Chromatography, Gas; Female; Homovanillic Acid; Humans; Levodopa; Male; Mass Spectrometry; Mid | 1997 |
Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease.
Topics: Aged; Analysis of Variance; Blood Platelets; Female; Humans; Male; Middle Aged; Monoamine Oxidase; P | 2001 |
Plasma beta-phenylethylamine in Parkinson's disease.
Topics: Aged; Female; Gas Chromatography-Mass Spectrometry; Humans; Male; Middle Aged; Parkinson Disease; Ph | 2000 |